Novo Nordisk CagriSema shows weight loss edge over tirzepatide in trials
Go back to Novo Nordisk CagriSema shows weight loss edge over tirzepatide in trials| NOVO-NORDISK A/S (NYSE: NVO) | Delayed: 39.67 +0.61 (1.56%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $39.06 | 52 Week High | $59.00 | |||
| Open | $39.39 | 52 Week Low | $32.80 | |||
| Day High | $39.75 | P/E | N/A | |||
| Day Low | $39.24 | EPS | $0.00 | |||
| Volume | 3,521,904 | |||||



